soul trial oral semaglutide cardiovascular outcomes 2024 results Reduces CV Events in T2DM โ (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine ๐งช T2DM + ASCVD/CKD ๐ Oral semaglutide 14 mg vs placebo ๐ Semaglutide cardiovascular outcomes align more
Description
SELECT showed that group gets significant MACE reduction, which is a mortality-relevant outcome
If you want to understand how your health and fitness are connected to your medication routine, a more specialised tool is worth exploring see our guide to health and fitness applications for GLP-1 users for a broader look at what is available
[DOI] [PubMed] [Google Scholar] 720.Parkinson J.R., Chaudhri O.B., Kuo Y.T., Field B.C., Herlihy A.H., Dhillo W.S
Why are there so many versions of the same ad
Some require attention
